[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637510":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":16,"locations":24,"responsibleParty":87,"collaborators":89,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":95,"sex":101,"minAge":102,"maxAge":7,"enrollmentInfo":103,"targetDuration":7,"studyType":106,"phases":7,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":121,"whyStopped":7,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","OTHER",null,[9,13],{"name":10,"affiliation":11,"role":12},"Pau Llàcer Iborra, MD PhD","Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal (FIBioHRC)","PRINCIPAL_INVESTIGATOR",{"name":14,"affiliation":15,"role":12},"Luis Manzano Espinosa, MDPhD","Hospital Universitario Ramón y Cajal",[17,21],{"name":10,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","0034 913368000","paullacer@hotmail.com",{"name":22,"role":18,"phone":7,"phoneExt":19,"email":23},"Cristina Fernández Soler","cfsoler@salud.madrid.org",[25,43,59,73],{"facility":26,"status":7,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Hospital de Olot i Comarcal de la Garrotxa","Olot","Girona","17800","Spain","ES",{"type":33,"coordinates":34},"Point",[35,36],2.49012,42.18096,{"lat":36,"lon":35},[39],{"name":40,"role":18,"phone":41,"phoneExt":7,"email":42},"Joan Carles Trullas","0034 972275200","direccio@hospiolot.com",{"facility":44,"status":7,"city":45,"state":45,"zip":46,"country":30,"countryCode":31,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Hospital Universitario Ramon y Cajal","Madrid","28034",{"type":33,"coordinates":48},[49,50],-3.70256,40.4165,{"lat":50,"lon":49},[53,55,57],{"name":10,"role":18,"phone":54,"phoneExt":7,"email":20},"0034913368000",{"name":56,"role":18,"phone":54,"phoneExt":7,"email":23},"Cristina Fernandez Soler",{"name":58,"role":12,"phone":7,"phoneExt":7,"email":7},"Pau Llacer Iborra, MD PhD",{"facility":60,"status":7,"city":61,"state":45,"zip":62,"country":30,"countryCode":31,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Hospital Universitario Puerta de Hierro Majadahonda","Majadahonda","28222",{"type":33,"coordinates":64},[65,66],-3.87182,40.47353,{"lat":66,"lon":65},[69],{"name":70,"role":18,"phone":71,"phoneExt":7,"email":72},"Marta Cobo","0034 911916000","atepac.hpth@salud.madrid.org",{"facility":74,"status":7,"city":75,"state":75,"zip":76,"country":30,"countryCode":31,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Hospital Clínico Universitario de Valencia","Valencia","46010",{"type":33,"coordinates":78},[79,80],-0.37966,39.47391,{"lat":80,"lon":79},[83],{"name":84,"role":18,"phone":85,"phoneExt":7,"email":86},"Sandra Villar","0034 9619735 00","hclinico_saip@gva.es",{"type":88,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[90],{"name":91,"class":92},"Carlos III Health Institute","OTHER_GOV","100637510","urinary-chloride-and-sodium-changes-and-residual-congestion-in-acute-heart-failure-100637510",false,"NCT07597512","Urinary Chloride and Sodium Changes and Residual Congestion in Acute Heart Failure","Association of Urinary Chloride and Sodium Dynamics With Multiparametrically Assessed Residual Congestion in Acute Heart Failure (CLORINA-IC)","CLORINA-IC","Inclusion Criteria:\n\n* Provision of written informed consent prior to any study-related procedures;\n* Age ≥ 18 years;\n* Episode of AHF requiring hospital admission and treatment with intravenous furosemide;\n* New York Heart Association (NYHA) functional class II-IV;\n* NT-proBNP \\>1000 pg\u002FmL or BNP \\>250 pg\u002FmL, measured within a period not exceeding 24 hours prior to inclusion;\n* Transthoracic echocardiogram performed within the previous 24 months. All LVEF categories will be included: reduced LVEF (\\\u003C40%), mildly reduced LVEF (41-49%), and preserved LVEF (≥50%). In patients with preserved LVEF (HFpEF), congruent structural and\u002For functional echocardiographic abnormalities are required (left ventricular hypertrophy defined as septal or posterior wall thickness ≥11 mm, E\u002Fe' \\>9, or left atrial volume \\>32 mL\u002Fm²);\n* Signs of fluid overload, with at least two of the following: jugular venous distension (at least up to the sternocleidomastoid level, \\~10 cm), lower limb edema, ascites, or pleural effusion confirmed by chest radiography or lung ultrasound\n* Treatment with oral furosemide at a dose of at least 40 mg\u002Fday within the previous month.\n\nExclusion Criteria:\n\n* Symptomatic hyponatremia or plasma sodium level ≤125 mmol\u002FL;\n* Hemoglobin \\\u003C9 g\u002FdL;\n* Hypokalemia: serum potassium \\\u003C3 mEq\u002FL;\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m²;\n* Hemodynamic instability at admission, defined as symptomatic hypotension;\n* Acute coronary syndrome, cardiogenic shock, or admission to the intensive care unit (ICU);\n* Severe infection (e.g., pneumonia, sepsis, leukocyte count ≥12,000\u002FμL, C-reactive protein \\>50 mg\u002FL, or positive COVID-19 test);\n* Requirement for inotropic agents;\n* Life expectancy \\\u003C3 months or, in the investigator's judgment, inability to comply with study procedures.","ALL","18 Years",{"count":104,"type":105},223,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn how changes in urinary sodium and chloride levels relate to fluid overload and short-term outcomes in patients hospitalized with acute heart failure (AHF). The main questions it aims to answer are:\n\n* Do changes over time in urinary sodium and chloride reflect how well excess fluid is being removed during hospitalization?\n* Are these changes associated with residual congestion at discharge and with the risk of worsening heart failure or death after discharge?\n\nParticipants hospitalized for AHF and treated with intravenous diuretics as part of their usual care will have clinical assessments, blood and urine tests, and echocardiographic evaluations collected at several time points during their hospital stay. Researchers will also record clinical outcomes, including worsening heart failure or death, at 30 days and 3 months after discharge.",[109,110,111],"Acute Heart Failure (AHF)","Heart Failure","Congestion",[113,114,115,111,116,117,118,119,120],"Acute Heart Failure","Heart failure","Biomarkers","Urinary chloride","Urinary sodium","Diuretics","point of care ultrasound","POCUS","NOT_YET_RECRUITING","2026-05-19",{"date":124,"type":125},"2026-05-22","ACTUAL",{"date":127,"type":105},"2026-05",{"date":129,"type":105},"2028-12-31",{"name":5,"class":6},4]